Literature DB >> 2714884

A case-control study of cancer of endometrium in Athens.

Y Koumantaki1, A Tzonou, E Koumantakis, E Kaklamani, D Aravantinos, D Trichopoulos.   

Abstract

Eighty-three women with invasive adenocarcinoma of the endometrium and 164 control women hospitalized for various orthopedic conditions were interviewed regarding demographic, reproductive, socio-economic and biomedical characteristics, including their use of tobacco, drugs and exogenous estrogens. The data were analyzed by modelling rate ratio (r) through multiple logistic regression. The main results were as follows: women with invasive adenocarcinoma of the endometrium had earlier menarche (r = 0.82 for every additional year; one-tailed p approx. 0.04), later menopause (r = 1.50 for a 5-year difference; one-tailed p approx. 0.004), and fewer live-born children (r = 0.86 for every additional child; one-tailed p approx. 0.08); they were also taller (r = 1.33 for a 5-cm difference; one-tailed p approx 0.03), whereas weight, adjusted for height, was not a statistically significant risk indicator (one-tailed p approx. 0.38). Regular use of combination oral contraceptives was associated with a reduced risk of endometrial cancer (r = 0.56), whereas intake of menopausal estrogens for more than 6 months was associated with an increased risk (r = 2.04); however, because of the low frequency of use of exogenous estrogen preparations in Greece, neither of these 2 results was statistically significant. Tobacco smoking was associated with a significantly reduced risk of endometrial cancer; smoking 15-20 cigarettes per day for 20 years was associated with a rate ratio of 0.49 (one-tailed p approx. 0.03). The protective effect of tobacco smoking was evident only among post-menopausal women. These results indicate that the risk profile of endometrial cancer is similar in high-risk and low-risk countries, and underline the importance of unopposed estrogenic stimulation in the pathogenesis of this cancer.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2714884     DOI: 10.1002/ijc.2910430509

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  Oral contraceptives and the risk of endometrial cancer.

Authors:  F Levi; C La Vecchia; C Gulie; E Negri; V Monnier; S Franceschi; J F Delaloye; P De Grandi
Journal:  Cancer Causes Control       Date:  1991-03       Impact factor: 2.506

2.  Harvard report on cancer prevention. Causes of human cancer. Reproductive factors.

Authors: 
Journal:  Cancer Causes Control       Date:  1996-11       Impact factor: 2.506

3.  Bone mineral density, sex steroids, and mineral metabolism in premenopausal smokers.

Authors:  N Ortego-Centeno; M Muñoz-Torres; J Hernandez-Quero; A Jurado-Duce; J de la Higuera Torres-Puchol
Journal:  Calcif Tissue Int       Date:  1994-12       Impact factor: 4.333

4.  Aspirin, NSAID, and acetaminophen use and the risk of endometrial cancer.

Authors:  Akila N Viswanathan; Diane Feskanich; Eva S Schernhammer; Susan E Hankinson
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

5.  A prospective cohort study of cigarette smoking and the risk of endometrial cancer.

Authors:  P D Terry; A B Miller; T E Rohan
Journal:  Br J Cancer       Date:  2002-05-06       Impact factor: 7.640

6.  Parity and endometrial cancer risk: a meta-analysis of epidemiological studies.

Authors:  Qi-Jun Wu; Yuan-Yuan Li; Chao Tu; Jingjing Zhu; Ke-Qing Qian; Tong-Bao Feng; Changwei Li; Lang Wu; Xiao-Xin Ma
Journal:  Sci Rep       Date:  2015-09-16       Impact factor: 4.379

7.  Risk Factors for Endometrial Cancer: Results from a Hospital-Based Case-Control Study

Authors:  Maryam Ghanbari Andarieh; Mouloud Agajani Delavar; Dariush Moslemi; Sedighe Esmaeilzadeh
Journal:  Asian Pac J Cancer Prev       Date:  2016-10-01

8.  Dietary factors and the risk of endometrial cancer: a case--control study in Greece.

Authors:  A Tzonou; L Lipworth; A Kalandidi; A Trichopoulou; I Gamatsi; C C Hsieh; V Notara; D Trichopoulos
Journal:  Br J Cancer       Date:  1996-05       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.